Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTPA | P49638 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286174 | 0.85 | ACE (0.41) | LMNAMAPTNR1I2 | |
| SCHEMBL1285646 | 0.85 | NR1I2 (0.68) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL1285440 | 0.75 | TTPA (0.64) | TTPALMNAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL27696980 | 0.74 | LMNA (0.89) | TTPALMNAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL3272328 | 0.74 | LMNA (0.78) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL6385400 | 0.74 | LMNA (0.71) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL5909543 | 0.74 | TTPA (0.74) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL1861568 | 0.73 | LMNA (0.80) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL5966742 | 0.73 | LMNA (0.80) | TTPALMNAMAPTMEN1KMT2A | |
| SCHEMBL6390586 | 0.73 | LMNA (0.70) | TTPALMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791155-B2 | Chroman derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | claimed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | claimed |
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2012148927-A2 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148929-A2 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | TTPA 1199/4885LMNA 900/4885MAPT 3600/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | TTPA 1199/4885LMNA 900/4885MAPT 3600/4885 |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | TTPA 401/4885LMNA 637/4885MAPT 115/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | TTPA 401/4885LMNA 637/4885MAPT 115/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | TTPA 240/4885LMNA 806/4885MAPT 4766/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | TTPA 415/4885LMNA 1713/4885MAPT 875/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | TTPA 240/4885LMNA 806/4885MAPT 4766/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | TTPA 415/4885LMNA 1713/4885MAPT 875/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | TTPA 401/4885LMNA 637/4885MAPT 115/4885 |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | ALOX12, ALOX15, ALOX15B | TTPA 1253/4885LMNA 981/4885MAPT 3347/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | TTPA 224/4885LMNA 1125/4885MAPT 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.